$100,000.00 in Sales Expected for OvaScience Inc. (OVAS) This Quarter
Wall Street analysts expect OvaScience Inc. (NASDAQ:OVAS) to report $100,000.00 in sales for the current quarter, according to Zacks. Two analysts have made estimates for OvaScience’s earnings, with the lowest sales estimate coming in at $90,000.00 and the highest estimate coming in at $100,000.00. OvaScience posted sales of $200,000.00 in the same quarter last year, which would indicate a negative year over year growth rate of 50%. The business is expected to announce its next earnings report on Thursday, November 2nd.
According to Zacks, analysts expect that OvaScience will report full year sales of $100,000.00 for the current fiscal year, with estimates ranging from $300,000.00 to $330,000.00. For the next year, analysts anticipate that the firm will report sales of $2.95 million per share, with estimates ranging from $300,000.00 to $5.59 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for OvaScience.
OvaScience (NASDAQ:OVAS) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.45) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.47) by $0.02. OvaScience had a negative net margin of 16,132.47% and a negative return on equity of 69.13%. The firm had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.09 million. During the same period in the previous year, the firm posted ($0.62) earnings per share. The firm’s revenue was down 55.6% on a year-over-year basis.
Several analysts have commented on OVAS shares. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of OvaScience in a report on Thursday, June 22nd. Zacks Investment Research downgraded shares of OvaScience from a “hold” rating to a “sell” rating in a report on Thursday, July 13th.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. EcoR1 Capital LLC acquired a new stake in shares of OvaScience in the first quarter valued at approximately $6,568,000. Jennison Associates LLC raised its holdings in shares of OvaScience by 0.4% in the second quarter. Jennison Associates LLC now owns 2,191,258 shares of the biotechnology company’s stock valued at $3,418,000 after purchasing an additional 7,731 shares during the last quarter. GMT Capital Corp raised its holdings in shares of OvaScience by 43.6% in the first quarter. GMT Capital Corp now owns 757,114 shares of the biotechnology company’s stock valued at $1,416,000 after purchasing an additional 229,719 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of OvaScience by 4,654.1% in the second quarter. Legal & General Group Plc now owns 458,822 shares of the biotechnology company’s stock valued at $713,000 after purchasing an additional 449,171 shares during the last quarter. Finally, Sabby Management LLC raised its holdings in shares of OvaScience by 774.7% in the first quarter. Sabby Management LLC now owns 423,775 shares of the biotechnology company’s stock valued at $792,000 after purchasing an additional 375,325 shares during the last quarter. Institutional investors own 56.28% of the company’s stock.
OvaScience (NASDAQ:OVAS) opened at 1.36 on Tuesday. OvaScience has a 12 month low of $1.25 and a 12 month high of $8.98. The company’s 50-day moving average is $1.45 and its 200-day moving average is $1.49. The stock’s market capitalization is $48.53 million.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/19/100000-00-in-sales-expected-for-ovascience-inc-ovas-this-quarter.html.
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.